HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA appropriations

This article was originally published in The Rose Sheet

Executive Summary

In a May 26 budget markup, House Appropriations/Agriculture Subcommittee more than doubles FDA's budget for buildings and facilities to just over $18 mil. in FY 1995 from $8.4 mil. in FY 1994. The increase is intended to cover the cost of replacing the agency's Los Angeles laboratory, which Chairman Richard Durbin (D- IL) called a "disaster" and a "dangerous place to work." The committee also provided FDA with $79 mil. in Rx user fees, consistent with funding levels authorized by the 1992 Prescription Drug User Fee Act, but denied the $228 mil. in unauthorized user fees requested by the Administration ("The Rose Sheet" Feb. 14, p. 7). Excluding the user fee revenues, the subcommittee set total FDA funding at $914 mil. In 1994, FDA was appropriated $873 mil., plus $61 mil. in user fees

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel